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Prostatic carcinoma is the most frequent cancer in males in the Western world. 
A significant proportion of these cancers have a recurrent translocation involving 
ETS family genes, which leads to the overexpression of ERG transcription factor. 
Prostate cancers, which bear this mutation, differ in a number of features, including 
tumor microenvironment. One of the components of the tumor microenvironment 
is FOXP3 positive lymphocytes, which may participate in breaking  immuno - 
surveillance and promoting tumor growth. 
The aim of the study was to analyze the relationships between ERG expression, 
number of FOXP3 positive cells and other features of the tumor.
The study group consisted of 65 cases. Tissue microarrays composed of 2 mm tis-
sue cores were used for immunohistological evaluation. Immunohistochemistry for 
ERG and FOXP3 was performed according to the routinely applied protocol. The 
FOXP3 positive cells were counted and the results were expressed as the number 
of cells per mm2.
The average number of FOXP3 positive cells was 33.30/mm2 for all cases, 21.43/
mm2 for the ERG negative and 42.28/mm2 for the ERG positive group (p < 0.02). 
There were no significant relationships between FOXP3 positive cell count and any 
other parameters studied.
Our results suggest that the immune response may differ between ERG negative 
and ERG positive prostatic carcinomas.
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Introduction
As Western society ages, the frequency of some 
cancers decreases, others become curable, but there 
are still some which occur even more often and re-
main a serious problem. One such tumor is prostate 
cancer. It has become the most prevalent cancer in 
some countries and an important cause of death 
[1]. In terms of prognosis, prostate cancer is a het-
erogeneous disease, but the number of established 
prognostic factors is limited, which often makes the 
therapy planning suboptimal. The most frequent 
single genetic event in prostate cancer is a translo-
cation involving genes of the ETS family, most often 
ERG. Such translocation, which leads to ERG pro-
tein expression, is seen in about half of European and 
American prostate cancer cases. The prognostic sig-
nificance of this phenomenon remains, however, con-
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troversial. Prostatic carcinomas bearing the translo-
cation involving ETS genes may differ in a number of 
features. For example, in one of the previous studies 
we demonstrated that they are characterized by high-
er microvessel density [2]. Regulatory T lymphocytes 
(Tregs), well identified by FOXP3 expression, are the 
negative regulators of the immune response. They 
are known to be involved in some physiological pro-
cesses, e.g. the progression of labor [3], but were also 
shown to influence the prognosis in several cancers 
[4, 5, 6]. 
The aim of the present study was to analyze the 
relationships between the number of FOXP3 positive 
cells and ERG status as well as other basic parameters 
of prostate cancer.
Material and methods
The material of the study consisted of unselect-
ed prostatectomy specimens obtained from the files 
of the Pathology Department. The slides were re-
viewed by an urologic pathologist and reclassified 
according to the current Gleason system as well as 
the latest TNM criteria [7, 8, 9]. Nerve invasion, 
lymphovascular invasion, status of surgical margins, 
presence of multiple tumor foci and production of 
mucin were also reevaluated. The positive margins 
were classified as focal or extensive [10]. The approx-
imate volume of the prostate was estimated using 
the ellipsoid volume formula v = a*b*c*0.523598, 
where a, b and c are the dimensions of the gland 
registered at gross examination. For each case, one 
representative section was chosen. On the slide, the 
region of interest containing carcinoma tissue was 
marked and its extent was subsequently copied to 
the surface of the paraffin block. For the tissue mi-
croarray (TMA) production a manual device (Histo-
pathology Inc., Hungary) was used. On each paraf-
fin block, from the area marked as cancer two 2 mm 
cores were obtained and transferred into a recipient 
block. The case numbers together with the respec-
tive location in the TMA were entered in an Excel 
(Microsoft Inc., USA) spreadsheet. The upper-left 
corner of the TMA was left empty to allow inves-
tigators proper orientation of the obtained slides. 
From the TMA paraffin blocks, 2 mm sections were 
prepared and stained with hematoxylin-eosin (HE) 
and immunohistochemically. HE slides were used to 
control quality of tissue selection and to determine 
the Gleason score of particular spots. Immunohisto-
chemistry was processed according to the protocol 
used on a routine basis. For ERG staining (Fig. 1), 
a rabbit monoclonal antibody (clone EPR3864), 
produced by Abcam, was used in a 1 : 200 dilution. 
Antigen retrieval was performed by immersing the 
slides in citrate buffer and heating them for 30 min-
utes. For FOXP3 staining (Fig. 2), mouse monoclo-
nal antibody (clone 236A/E7), produced by Abcam, 
was used in a 1 : 100 dilution. In this case, heating 
in EDTA for 30 minutes was performed for antigen 
retrieval. The LabVision detection system (Thermo 
Scientific, USA) was used for each staining. The re-
sults of the ERG staining were scored as positive 
when unequivocal nuclear staining was present; very 
faint nuclear as well as any cytoplasmic reaction was 
ignored, as previously reported [11]. The FOXP3 
expressing cells were counted in each tissue microar-
ray core and the results were expressed as the num-
ber of cells per mm2. The person who counted the 
cells was blind to the ERG status as well as to other 
data under study. The results were collected in the 
Excel spreadsheet containing the case numbers. Sta-
tistics were calculated with Statistica 10 (StatSoft 
Inc., USA). Mann-Whitney U and Kruskal-Wallis 
ANOVA tests were used, as appropriate. The signif-
icance level was set to 0.05.
Results
The study group consisted of 65 cases. The aver-
age age of the patients was 61.26 years (ranging from 
38 to 73 years, SD 6.62). The average PSA level was 
12.22 ng/ml (ranging from 1.89 to 52.20, SD 9.71). 
The average volume of the prostate was 39.39 cm3 
(ranging from 12.57 to 91.89, SD 18.43). Only one 
case showed lymph node metastases. In 23 cases 
(35.38%) the disease was organ confined. Lympho-
vascular invasion was present in 47 cases (72.31%). 
The detailed characteristics are shown in Table I.
Twenty-eight cases (43.1%) were ERG negative 
and 37 (56.9%) were ERG positive (Fig. 1). The av-
erage number of FOXP3 positive cells (Fig. 2) was 
33.30/mm2 (SD 33.07). For ERG negative cases the 
average number of FOXP3 positive cells was 21.43/
mm2 (SD 16.90) while for ERG positive cases it was 
42.28/mm2 (SD 39.21). The difference was statisti-
cally significant (p < 0.02; Fig. 3). The number of 
FOXP3 positive cells did not show any correlations 
with other parameters included in the analysis, such 
as age, tumor stage, grade, prostate size or PSA level 
(data not shown).
Discussion
Prostatic cancer, being responsible for almost 
30,000 deaths per year in the United States [1] and 
over 4000 a year in Poland [12], is among the most 
frequent and important cancers in men. Individual 
prognostication is difficult as in other malignancies, 
but in prostatic carcinoma particularly relevant, since 
not all the cases are aggressive. As a consequence, 
a significant proportion of patients receive therapy, 
which is of little, if any, benefit to them. On the other 
hand, patients who experience relapse and dissemi-
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nation of the disease may not be offered any definite 
treatment [13, 14]. It is thus of primary importance 
to recognize additional prognostic parameters, which 
could potentially be helpful in adjusting appropriate 
therapy. In this context, the immunological response 
seems to be worth investigating, and it has already 
been proposed to use tumor vaccines in prostate can-
cer [15]. Proper understanding of immunological 
processes is crucial, as many components of the tu-
mor microenvironment, including macrophages, dif-
ferent classes of lymphocytes, NK cells, plasma cells, 
neutrophils, eosinophils and mast cells, participate in 
the immune response [16, 17, 18, 19]. 
A class of cells which has gained special interest and 
been extensively studied in cancers is regulatory lym-
phocytes [4, 5, 6, 20]. Merlo et al. [4] published an 
analysis of regulatory lymphocytes in breast carcino-
ma, in which they reported a significant survival bene-
fit in FOXP3 negative cases. This effect was observed 
both in lymph node negative and positive cases, which 
was associated with a lower risk of metastatic disease, 
but not with the risk of local recurrence. Petersen et al. 
[5] reviewed cases of non-small-cell pulmonary carci-
nomas and found that patients with a higher FOXP3 
positive/overall T lymphocyte ratio were at greater 
risk of relapse. Salama et al. [6] analyzed the popu-






Grade Gleason’s No. (%) grade group No. (%)
6 (3+3) 18 (27.69%) 1 18 (27. 69%)
7 (3+4) 27 (41.54%) 2 27 (41.54%)
7 (4+3) 12 (18.46%) 3 12 (18.46%)
8 (3+5) 3 (4.62%) 4 4 (6.15%)
8 (4+4) 1 (1.54%)
9 (4+5) 4 (6.15%) 5 4 (6.15%)
Margin status No. (%)
negative 30 (46.15%)
positive – focal 17 (26.15%)
positive – extensive 18 (27.69%)
Fig. 1. Carcinoma of the prostate showing strong expres-
sion of ERG transcription factor. Immunohistochemistry, 
400×
Fig. 2. Single FOXP3 positive cells in the stroma of a carci-
noma of the prostate. Immunohistochemistry, 400×
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lation of lymphocytes in colorectal cancer and found 
a relationship between FOXP3 positive cells and tu-
mor stage, but there were no correlations with other 
clinicopathological parameters. FOXP3 positive cell 
number proved to be an independent prognostic fac-
tor, while other analyzed subsets of lymphoid cells did 
not. Interestingly, a higher number of FOXP3 positive 
cells correlated with better prognosis, and additionally 
these cells were not associated with the microsatellite 
instability status. Rubinkiewicz et al. [20], who ana-
lyzed colorectal adenoma and cancers, observed that 
the mean FOXP3/CD4 cell ratio increases during the 
progression to malignancy.
The number of studies on FOXP3 positive cells 
in prostatic carcinoma is more limited. Yokokawa et 
al. [21] analyzed peripheral blood Tregs in prostate 
cancer patients and found that the number of these 
cells was increased in metastatic disease. Tregs of these 
patients showed an increased ability to suppress anti-
gen-dependent T-lymphocyte proliferation. Ebelt et al. 
[22] compared the lymphocyte populations in normal, 
hyperplastic and neoplastic prostate and reported that 
the foci of prostate cancer are surrounded by clusters of 
T lymphocytes. In these clusters, as well as in the sparse 
tumor infiltrating lymphocytes, the ratio of CD4 posi-
tive to CD8 positive cells was increased in comparison 
to benign tissue. Moreover, the cancer-associated lym-
phocytes were characterized by significantly reduced 
interferon gamma production and perforin expression, 
which might lead to a disturbed effector response. The 
same group of scientists [23] demonstrated that the 
peritumoral lymphocyte clusters contained regulatory 
lymphocytes, which actively silence the immune re-
sponse against cancer. Miller et al. [24] found a high-
er number of regulatory T lymphocytes in peripheral 
blood of patients with prostatic carcinoma, as well as 
within tumor tissue. They also showed that these cells 
are indeed actively immunosuppressive in vitro, and 
that the prostate cancer supernatant has a chemotactic 
effect on Tregs. Additionally, Ebelt et al. [23] found no 
correlations between the number of regulatory lym-
phocytes in prostate cancer and tumor stage or grade, 
which is consistent with the results of our study. Sfanos 
et al. [25] found that tumor infiltrating TH lympho-
cytes in prostate cancer include predominantly TH1, 
TH17 and Treg (FOXP3 positive) subtypes, while TH2 
are virtually nonexistent, although in some studies 
TH2 cells were associated with the pathogenesis of this 
malignancy [26]. Interestingly, despite the fact that 
the level of interleukin 17 and, to some degree, the 
level of interferon gamma were dependent on Gleason 
score of the tumor, FOXP3 expression did not show 
any correlation with the tumor grade [25], which is 
in agreement with our findings. Furthermore, the 
same authors [27] found that in prostate cancer CD8 
positive cells are oligoclonal and express high levels 
of inhibitory receptor PD-1, which is suggested to be 
a mechanism of tumor-induced tolerance. Kiniwa et al. 
[28] also analyzed the CD8 positive FOXP3 positive 
cells in prostate cancer. They cultured Treg cells de-
rived from malignant tissue, purified them by fluores-
cence-activated cell sorting and analyzed them togeth-
er with their location in the prostate cancer samples by 
using confocal microscopy. Their results indicate that 
CD8 positive FOXP3 positive Treg cells suppress im-
mune responses and this phenomenon may be regulat-
ed by the toll-like receptor 8 ligands.
Di Carlo et al. [29] found that the prostate can-
cer cells lack interleukin 7 and BAFF/BLyS expres-
sion seen in non-neoplastic prostate and suggested 
that it may be the main mechanism of tumor escape 
from immunosurveillance. In addition, Sorrentino et 
al. [30] analyzed the changes in tumor infiltrating 
lymphocytes associated with hormonal neoadjuvant 
therapy. They found that the number of both effec-
tor and regulatory lymphocytes was increased, which 
let them deduce that the net effect of hormonal 
treatment on the immune response is insignificant. 
In contrast to the T cells, a proportion of which are 
involved in the anti-cancer response, the B cells are 
thought to have a tumor protecting and promoting 
effect. Woo et al. [31] found an increased number 
of B-lymphocytes in the immediate surroundings of 
prostatic cancer in comparison to the tissue areas dis-
tant from malignant cells. 
To the best of our knowledge, this is the first study 
suggesting that different subtypes of prostatic carci-
noma may differ in their ability to induce an immu-
nologic response. 
The study was supported by Jagiellonian University 
grant no. K/ZDS/006384.
The authors declare no conflict of interest.
Fig. 3. Differences in the number of FOXP3 positive cells 
between ERG negative and ERG positive carcinomas of 
the prostate. Central point is arithmetic mean, box is mean 
± standard deviation, whisker is range
 ERG– ERG+
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